Company intelligence / Profile preview
Arnatar Therapeutics
San Diego, California, United Statesarnatar.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Arnatar is a preclinical stage biotechnology company developing RNA therapeutics. Their lead program ART1 for hypertension is scheduled to enter clinical trials in mid-2024, with additional preclinical assets for metabolic diseases and rare diseases planned to enter the clinic in early 2025.
- Therapeutic areas
- Metabolic DisordersCardiovascularRare Diseases
- Modalities
- siRNA (small interfering RNA)ASO (antisense oligonucleotides)RNA therapeuticsantisense nucleic acid technology
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Beyond the preview
Go deeper on Arnatar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arnatar Therapeutics.